drugset / Trial / NCT02251847

The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients

NCT02251847

Phase 3 Unknown 400 enrolled IlDong Pharmaceutical Co Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate efficacy and safety of a combination therapy of rosuvastatin and ezetimibe versus monotherapy of rosuvastatin in hypercholesterolemia patients

Timeline

Start
2014-07
Primary completion
2015-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown 10 mg
Subject Rosuvastatin Small molecule 5 mg
Subject Rosuvastatin Small molecule 10 mg
Subject Rosuvastatin Small molecule 20 mg

Indications